27 July 2023, Seattle A surgical technology firm called Proprio in Seattle has revealed that it has received USD 43 million in Series B funding from both new and existing investors. The funding supports commercialization to meet Proprio’s AI-driven surgical navigation platform’s strong demand in the U.S. and abroad.
This year, the 510(k) clearance from the U.S. Food and Drug Administration (FDA) marked a key milestone for Proprio’s central surgical navigation technology, ParadigmTM. To create a real-time 3D visualization of surgery, Paradigm uses artificial intelligence and light field technologies. Volumetric IntelligenceTM, a special combination of medical imaging and real-time data from Paradigm’s sensor suite, is a service that Paradigm offers to surgeons.
The Paradigm method offers both surgeons and patients several benefits. Because there is no longer a requirement for intraoperative imaging, the patient and surgical team are exposed to less radiation. This increases the amount of care available to patients by saving up to 30 minutes per procedure. Paradigm provides high precision by swiftly registering imaging data to the anatomy inside surgical workflows, allowing surgeons to keep their attention on the patient.
Compared to current static techniques to surgical navigation, Proprio’s live, 3D, multi-modal data offers a substantial improvement, and the business hopes to expand its technology beyond its initial focus on spinal procedures.
According to Gabriel Jones, CEO and co-founder of Proprio, “We are just beginning to reveal the potential applications of Proprio’s technology and data.” “This financing comes at a critical time as we conduct our first-in-human cases and make Paradigm available to patients worldwide. These achievements demonstrate the Proprio Paradigm’s unmatched strengths and potential to change surgery.
“We have been looking for a startup that has the potential to use data to disrupt the traditional medical device industry at scale for a while now. Alf Grunwald, Executive Advisor of Bird B. AG, a global investment partnership with large stakes in surgical software and medical device manufacturing, said, “Proprio represents that kind of possibility and we are happy to join the investment group.
Proprio, a pioneer in surgical technology, is developing the New Way of SeeingTM in surgery. The Proprio Paradigm system synthesizes data from many inputs for exploring anatomy and surgical situations in 3D using developments in light field computer vision and AI. The goal of Proprio is to drastically enhance clinical and financial outcomes by utilizing cutting-edge AI and data collection tools that have the ability to offer surgical predictive intelligence. Leading investors in healthcare and technology, including DCVC, BOLD Capital Partners, Bird B. AG, Cota Capital, Intel, and HTC, support Proprio.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!